Imunon Inc Stock Today
| IMNN Stock | USD 0.91 0.01 1.11% |
Performance0 of 100
| Odds Of DistressOver 82
|
Imunon is selling at 0.91 as of the 19th of January 2025; that is 1.11 percent increase since the beginning of the trading day. The stock's open price was 0.9. Imunon has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 20th of December 2024 and ending today, the 19th of January 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 1st of March 1999 | Category Healthcare | Classification Health Care |
Imunon, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Imunon, Inc. was founded in 1982 and is based in Lawrenceville, New Jersey. Imunon operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 14.5 M outstanding shares of which 970.16 K shares are currently shorted by private and institutional investors with about 2.38 trading days to cover. More on Imunon Inc
Moving against Imunon Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Imunon Stock Highlights
| CEO President | Stacy Lindborg | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Imunon can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Imunon's financial leverage. It provides some insight into what part of Imunon's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Imunon Inc (IMNN) is traded on NASDAQ Exchange in USA. It is located in 997 Lenox Drive, Lawrenceville, NJ, United States, 08648 and employs 33 people. Imunon is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 13.24 M. Imunon Inc conducts business under Biotechnology sector and is part of Health Care industry. The entity has 14.5 M outstanding shares of which 970.16 K shares are currently shorted by private and institutional investors with about 2.38 trading days to cover.
Imunon Inc currently holds about 42.11 M in cash with (19.02 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.93, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Imunon Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Imunon is $13.24 Million. Roughly 91.88 (percent) of Imunon outstanding shares are held by general public with 1.09 % owned by insiders and only 7.03 pct. by outside corporations. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Imunon Ownership Details
Imunon Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Tower Research Capital Llc | 2024-09-30 | 4.9 K | |
| Morgan Stanley - Brokerage Accounts | 2024-09-30 | 2.1 K | |
| M&r Capital Management Inc | 2024-09-30 | 333 | |
| Group One Trading, Lp | 2024-09-30 | 129 | |
| Bank Of America Corp | 2024-09-30 | 118 | |
| Federation Des Caisses Desjardins Du Quebec | 2024-09-30 | 66.0 | |
| Ubs Group Ag | 2024-09-30 | 21.0 | |
| Jones Financial Companies Lllp | 2024-09-30 | 5.0 | |
| Game Plan Financial Advisors, Llc | 2024-09-30 | 2.0 | |
| Sabby Management Llc | 2024-09-30 | 608.2 K | |
| Geode Capital Management, Llc | 2024-09-30 | 125.9 K |
Imunon Historical Income Statement
Imunon Stock Against Markets
Imunon Corporate Management
| CPA CPA | Exec CFO | Profile | |
| Nicholas MD | Ex Officer | Profile | |
| Susan Eylward | General Secretary | Profile | |
| David Gaiero | Chief Officer | Profile | |
| Sebastien MD | Executive Officer | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Imunon Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Imunon. If investors know Imunon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Imunon listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Imunon Inc is measured differently than its book value, which is the value of Imunon that is recorded on the company's balance sheet. Investors also form their own opinion of Imunon's value that differs from its market value or its book value, called intrinsic value, which is Imunon's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Imunon's market value can be influenced by many factors that don't directly affect Imunon's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Imunon's value and its price as these two are different measures arrived at by different means. Investors typically determine if Imunon is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Imunon's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.